Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EBT (2020 - 2025)

Rani Therapeutics Holdings has reported EBT over the past 6 years, most recently at -$8.5 million for Q4 2025.

  • Quarterly results put EBT at -$8.5 million for Q4 2025, up 45.95% from a year ago — trailing twelve months through Dec 2025 was -$40.4 million (up 28.65% YoY), and the annual figure for FY2025 was -$40.4 million, up 28.65%.
  • EBT for Q4 2025 was -$8.5 million at Rani Therapeutics Holdings, down from -$7.9 million in the prior quarter.
  • Over the last five years, EBT for RANI hit a ceiling of -$5.5 million in Q2 2021 and a floor of -$28.7 million in Q3 2021.
  • Median EBT over the past 5 years was -$13.9 million (2022), compared with a mean of -$14.1 million.
  • Biggest five-year swings in EBT: crashed 895.93% in 2021 and later surged 45.95% in 2025.
  • Rani Therapeutics Holdings' EBT stood at -$13.3 million in 2021, then plummeted by 30.26% to -$17.4 million in 2022, then increased by 19.15% to -$14.1 million in 2023, then decreased by 11.86% to -$15.7 million in 2024, then surged by 45.95% to -$8.5 million in 2025.
  • The last three reported values for EBT were -$8.5 million (Q4 2025), -$7.9 million (Q3 2025), and -$11.2 million (Q2 2025) per Business Quant data.